Biosig Technologies (NASDAQ:STEX) Chairman Morgan Lee Lekstrom Purchases 147,000 Shares

Biosig Technologies, Inc. (NASDAQ:STEX) Chairman Morgan Lee Lekstrom acquired 147,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The shares were purchased at an average price of $1.04 per share, with a total value of $152,880.00. Following the completion of the acquisition, the chairman owned 269,500 shares of the company’s stock, valued at $280,280. This represents a 120.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Morgan Lee Lekstrom also recently made the following trade(s):

• On Tuesday, April 14th, Morgan Lee Lekstrom sold 12,759 shares of Biosig Technologies stock. The shares were sold at an average price of $1.07, for a total value of $13,652.13.

Biosig Technologies Stock Up 3.7%

NASDAQ STEX traded up $0.04 during trading hours on Thursday, hitting $1.13. 1,930,935 shares of the company traded hands, compared to its average volume of 1,860,051. The stock has a 50-day simple moving average of $1.21. Biosig Technologies, Inc. has a twelve month low of $0.70 and a twelve month high of $14.11. The stock has a market cap of $204.69 million, a PE ratio of -0.12 and a beta of 1.58.

Biosig Technologies (NASDAQ:STEX) last issued its quarterly earnings results on Thursday, May 14th. The company reported $999.00 EPS for the quarter.

Analyst Upgrades and Downgrades

Several research analysts recently commented on STEX shares. Needham & Company LLC reduced their price target on Biosig Technologies from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday. Weiss Ratings raised Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 1st. Finally, Wall Street Zen cut Biosig Technologies from a “hold” rating to a “strong sell” rating in a research report on Sunday, April 5th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $8.00.

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.